Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
This event will also be webcast live. Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty David H Ilson, MD, PhD
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Rutika Mehta, MD, MPH
Associate Member in the Department of Gastrointestinal Oncology
Moffitt Cancer Center
Associate Professor in the Department
of Oncologic Sciences
University of South Florida
Tampa, Florida
Markus Moehler, MD
Head, Gastrointestinal Oncology
Research Center for Immunotherapy (FZI)
Past Chair of EORTC Gastrointestinal Cancer Group
Johannes Gutenberg-University Clinic
Mainz, Germany
Manish A Shah, MD
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Professor of Gastrointestinal Oncology
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York
Moderator Harry H Yoon, MD, MHS
Professor of Oncology
Enterprise Co-Leader
Gastrointestinal and Hepatobiliary/Pancreatic Cancer Research Program
Enterprise Vice-Chair, Gastrointestinal Cancer Disease Group
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota
This activity is supported by educational grants from Astellas, BeiGene Ltd, Bristol Myers Squibb, and Lilly.
MODULE 1: Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson
Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable microsatellite instability (MSI)-high/mismatch repair (MMR)-deficient gastric/gastroesophageal junction (GEJ) adenocarcinoma
Similarities and differences in the designs of the Phase III KEYNOTE-585 and MATTERHORN studies evaluating the addition of immunotherapy to chemotherapy in the perioperative setting for patients with biomarkerunselected resectable gastric/GEJ cancer
Recently presented efficacy and safety findings from KEYNOTE-585 and MATTERHORN
Key efficacy and safety outcomes from the Phase III CheckMate 577 trial evaluating adjuvant nivolumab for patients with esophageal or GEJ cancers after neoadjuvant chemoradiation therapy and surgery
FDA approval and appropriate identification of patients for adjuvant nivolumab
Ongoing Phase III studies evaluating neoadjuvant and/or adjuvant immune checkpoint inhibitors for patients with localized or locally advanced gastroesophageal cancers
MODULE 2: Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon
Clinical and biological factors, such as location of the primary tumor, histology, PD-L1 expression and MSI/MMR status, affecting the current choice of up-front therapy for patients with metastatic HER2-negative gastroesophageal cancers
Major efficacy and safety findings from Phase III studies, such as CheckMate 649 and KEYNOTE-859, evaluating the addition of first-line nivolumab and pembrolizumab to chemotherapy for advanced gastroesophageal adenocarcinoma
Published Phase III data sets, such as those from the CheckMate 648 and KEYNOTE-590 trials, demonstrating the efficacy and safety of first-line nivolumab and pembrolizumab-containing regimens for advanced esophageal/GEJ cancer
Mechanism of action of tislelizumab; similarities and differences in comparison to commercially available anti-PD-1/PD-L1 antibodies
Efficacy and safety findings from the Phase III RATIONALE-305 and RATIONALE-306 trials assessing tislelizumab in combination with chemotherapy for patients with previously untreated gastroesophageal cancers; potential role in clinical practice
MODULE 3: Emerging Role of Therapy Targeting Claudin 18.2 (CLDN18.2) in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah
Biological rationale for targeting CLDN18.2 in gastric/GEJ cancers; mechanism of antitumor activity of zolbetuximab
Design, eligibility criteria and key efficacy and safety results of the Phase III SPOTLIGHT and GLOW trials evaluating zolbetuximab in combination with chemotherapy as first-line treatment for patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
Potential role of zolbetuximab in clinical practice and implications for biomarker assessment
Rationale for and ongoing trials of the combination of zolbetuximab with anti-PD-1/PD-L1 antibodies for advanced gastric/GEJ cancers
Other novel CLDN18.2-targeted strategies under investigation
MODULE 4: Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Prof Moehler
Available data from the Phase III KEYNOTE-811 trial evaluating the addition of pembrolizumab to chemotherapy and trastuzumab for previously untreated HER2-positive advanced gastric/GEJ adenocarcinoma
Efficacy and safety findings from the DESTINY-Gastric01 and DESTINY-Gastric02 studies evaluating trastuzumab deruxtecan (T-DXd) for patients with progressive
HER2-positive gastric/GEJ cancer; optimal integration into clinical practice
Ongoing clinical trials attempting to further define the role of T-DXd for gastric/GEJ cancers, such as DESTINY-Gastric03 and DESTINY-Gastric04
Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab; published findings with zanidatamab/chemotherapy as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
Design, eligibility criteria and key efficacy and safety endpoints of the Phase III HERIZON-GEA-01 trial of up-front zanidatamab and chemotherapy with or without tislelizumab for HER2-positive gastroesophageal adenocarcinoma; estimated completion date
MODULE 5: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta
Published research findings with ramucirumab for metastatic gastroesophageal cancers and optimal integration into current clinical algorithms
Antitumor activity observed with ramucirumab for patients experiencing disease progression on an immune checkpoint inhibitor; implications for therapeutic sequencing
Rationale for, available data with and ongoing investigation of novel combination regimens for patients with gastric/GEJ cancer, such as ramucirumab with TAS-102 or ramucirumab with anti-PD-1 antibodies
Current role, if any, of anti-PD-1 monotherapy in the treatment of recurrent metastatic gastric/GEJ cancer
Key efficacy and safety findings from the Phase III RATIONALE-302 trial comparing tislelizumab to chemotherapy as second-line treatment for esophageal squamous cell carcinoma; potential role in clinical practice
Other promising agents and strategies under investigation for R/R gastroesophageal cancers
Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.
Learning Objectives
At the conclusion of this activity, participants should be able to
Use HER2 status, PD-L1 combined positive score, microsatellite instability/mismatch repair deficiency status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into treatment algorithms.
Incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer after disease progression on front-line therapy.
Appraise clinical trial findings supporting the use of neoadjuvant and/or adjuvant anti-PD-1/PD-L1 antibody therapy for patients with resectable gastric, GEJ and esophageal cancers, and discern the clinical applicability of various treatment strategies.
Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed or previously treated HER2-overexpressing gastric/GEJ cancer, and identify candidates for these approaches.
Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this emerging biomarker.
Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided prior to the program.
FACULTY— The following faculty reported relevant financial relationships with ineligible entities:
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from Astellas, BeiGene Ltd, Bristol Myers Squibb, and Lilly.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2024 ASCO Gastrointestinal Cancers Symposium is taking place.
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2024 ASCO Gastrointestinal Cancers Symposium.
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration deskwill be open at 5:30 PM PT on Thursday, January 18th. If you are interested in attending, please visit our registration desk outside the Golden Gate Ballroom — Salon A (B2 Level) at the San Francisco Marriott Marquishotel (780 Mission Street), within walking distance of the Moscone Convention Center (2 blocks). Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service. Clinicians in practice will be prioritized for seating first.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.
